Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Net Cash Flow (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Net Cash Flow for 14 consecutive years, with -$770559.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 950.21% year-over-year to -$770559.0, compared with a TTM value of -$2.4 million through Sep 2025, up 64.57%, and an annual FY2024 reading of -$5.6 million, up 7.38% over the prior year.
  • Net Cash Flow was -$770559.0 for Q3 2025 at Sunshine Biopharma, down from $1.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $28.5 million in Q2 2022 and bottomed at -$19.0 million in Q4 2022.
  • Average Net Cash Flow over 5 years is $454076.6, with a median of -$335777.0 recorded in 2021.
  • The sharpest move saw Net Cash Flow skyrocketed 41959.55% in 2022, then crashed 25270.25% in 2024.
  • Year by year, Net Cash Flow stood at -$335777.0 in 2021, then tumbled by 5547.28% to -$19.0 million in 2022, then skyrocketed by 84.23% to -$3.0 million in 2023, then soared by 36.95% to -$1.9 million in 2024, then surged by 59.12% to -$770559.0 in 2025.
  • Business Quant data shows Net Cash Flow for SBFM at -$770559.0 in Q3 2025, $1.8 million in Q2 2025, and -$1.6 million in Q1 2025.